Sign in with Google
bullish
Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer
932 Views21 May 2019 08:35
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 6-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Hanwha Ocean (042660 KS) Placement: Index Implications; Stock Appears Wildly Overvalued
- Toyota Industries (6201) - SURPRISE! It's a TOYODA Takeover Proposal (Good Governance May Not Win)
- Toyota Industries (6201 JP): A Rumoured Privatisation with Several Unknowns
- Laopu Gold (6181 HK): Global Index Inclusion Likely Derailed by Full Circulation
- Toyota (7203 JP) Tactical Outlook Following Toyota Industries (6201 JP) Privatization Rumors
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End30 May 2019
- Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal29 May 2019
- Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation23 May 2019
- Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)30 Apr 2019
- Hansoh Pharma (翰森制药) IPO: Takeaways from Recent 4+7 City Centralized Tender Results03 Jan 2019
x